Xcel Pharmaceuticals

Xcel Pharmaceuticals currently focus on neurology, a segment of the CNS market where a limited number of high-prescribing physicians.

Launch date

2001

Employees

Market cap

Enterprise valuation

San Diego California (HQ)

Date	Investors	Amount	Round
Apr 2001	New Enterprise Associates Greenspring Associates Domain Associates	$70.0m	Growth Equity VC
Jul 2002	New Enterprise Associates	$22.0m	Series B
Apr 2003	Ferrer Freeman & Company	$26.0m	Series C
Feb 2005	Valeant Pharmaceuticals International	N/A	Acquisition
Total Funding		AUD182m

Tech stackLearn more about the technologies and tools that this company uses.

Recent News about Xcel Pharmaceuticals